Plus Therapeutics, Inc. presented data on November 25, 2024, updating the progress of its ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal disease (LM) at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting.
The single intrathecal dose of Rhenium (186Re) Obisbemeda demonstrated a favorable response rate and median overall survival in LM patients. It achieved up to 8 times the absorbed radiation dose to the CNS subarachnoid space compared to standard external beam radiation.
Furthermore, the company received FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM. This marks a key next step in the integrated development plan for the therapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.